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The CYP11A1 gene encodes the cytochrome P450 side-chain cleavage enzyme,
which is essential for steroid formation. Recessive variants in this gene can lead
to impairment of sexual differentiation caused by a complete or partial loss of
steroid hormone production. The phenotypic spectrum in affected 46XY males
may vary from surgically repairable defects including cryptorchidism and
hypospadias to complete feminization of external gonads, accompanied by
symptoms of adrenal dysfunction.
Methods
Whole-exome sequencing (WES) of a 12-year-old male proband and his parents was
performed after a protracted diagnostic odyssey failed to uncover the cause of his pri-
mary adrenal insufficiency. Of note, the proband had early symptomatology and cor-
rective surgery for hypospadias, raising suspicion for a disorder of steroidogenesis.
Results
WES identified compound heterozygous variants in CYP11A1 including a novel
canonical splice site variant (c.425+1G>A) and a previously reported p.E314K
variant, which were consistent with a diagnosis of congenital adrenal insuffi-
ciency with partial 46XY sex reversal.
Conclusion
Congenital adrenal insufficiency with 46XY sex reversal is a rare disorder that is charac-
terized by dysregulation of steroid hormone synthesis, leading to adrenal and gonadal
dysfunction. In this report, we describe a patient with adrenal insufficiency, hypospa-
dias, and skin hyperpigmentation who was found to have a novel c.425+1G>A variant
in trans with the p.E314K variant in CYP11A1. We performed structural analyses to
examine the effect of the p.E314K variant on protein function and show that it falls in
the core of the protein may disrupt cholesterol binding in the active site.
Introduction
The CYP11A1 gene located in the long arm of chromo-
some 15 (15q23–q24) encodes the cholesterol side-chain
cleavage enzyme which converts cholesterol to preg-
nenolone, the first step for corticoid, mineralocorticoid,
and sexual hormone biosynthesis (Miller and Auchus
2011). CYP11A1 deficiency results in complete or partial
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adrenal insufficiency with a wide range of clinical mani-
festations. Severe or classical CYP11A1 deficiency mani-
fests with feminization of external genitalia in 46XY males
and severe early onset adrenal failure in the first few
hours or days of postnatal life. Mild or nonclassical
CYP11A1 deficiency is associated with adrenal insuffi-
ciency that can develop later in childhood and is accom-
panied by a spectrum of sexual development disorders
including precocious or delayed puberty (Katsumata et al.
2002; Hiort et al. 2005; Slominski et al. 2015).
Conclusion
In this report, we present a case of a 12-year-old male
with congenital adrenal insufficiency. Our patient began
having symptoms at 3 years old, which included lethargy,
hypoglycemia, hyperpigmentation, hypospadias, and bio-
chemical findings that confirmed adrenal insufficiency.
Clinical WES revealed compound heterozygous variants
in CYP11A including a novel c.425+1G>A splice site
mutation and a previously reported missense variant
(p.E314K). To our knowledge, this splice site variant has
not been reported previously but is likely pathogenic and
the cause of our patient’s primary adrenal insufficiency.
Case Description
The patient is a 12-year-old male, who is the second child
of nonconsanguineous parents. He was delivered via vagi-
nal route after induction of labor on the 34th week of
pregnancy due to HELLP (Hemolysis, Elevated Liver
enzymes, Low Platelet count) syndrome and toxemia and
was in the neonatal intensive care unit for 3 weeks for
recovery and treatment of neonatal jaundice. His birth
weight and length were 2.24 kg and 47 cm, respectively.
Upon examination of the external genitalia, hypospadias
were detected and later surgically repaired; cryptorchidism
was not a feature.
At 3 years of age, he began having severe diurnal epi-
sodes of lethargy and hypoglycemia. He was also noted to
have skin hyperpigmentation. Testing of hormone levels
revealed high adrenocorticotropic hormone (ACTH) and
low cortisol levels, suggestive of a primary adrenal insuffi-
ciency. An ultrasound and CT scan of the adrenal glands
at 3 years of age did not show abnormal findings. Genetic
testing for the NR0B1 (DAX1), which was involved in X-
linked congenital adrenal hypoplasia (MIM# 300200), was
negative. At 8 years of age, his bloodwork showed an
ACTH of 6 pg/mL (normal range 10–60 pg/mL), 17-
hydroxyprogesterone of ˂10 ng/dL (Prepubertal males:
<110 ng/dL), and testosterone levels below 2.5 ng/dL
(normal rage for males 6 months to 9 years: <7–20 ng/
dL). By 9 years of age, his ACTH was abnormally high at
261 pg/mL. Then at 10 years of age, his ACTH level
increased to 321.9 pg/mL and repeat testing a year later
revealed levels of 405 pg/mL. During his last medical visit,
no signs of altered puberty were noticed, and initiation of
corticosteroid treatment lead to the normalization of
ACTH levels (32.4 pg/mL post treatment). This also
improved his hyperpigmentation. No investigations were
performed for precocious puberty as his growth and
development were age appropriate. He did have a bone
age, however, at age 8 9/12 which showed a bone age of
8. The patient was also diagnosed with attention-deficit/
hyperactivity disorder (ADHD) and migraine. Currently,
he is under treatment with hydrocortisone (10 mg/m2/
day in the mornings and 5 mg/m2/day at night), fludro-
cortisone (50 lg/day), amphetamine-dextroamphetamine
(15 mg/day), and vitamin D (1000 units/day).
The patient presented to the Department of Clinical
Genomics (Mayo Clinic, Jacksonville, FL) with the finding
of primary adrenal insufficiency of unknown genetic
cause. Informed consent was obtained and blood samples
were collected from the patient and his parents for WES.
There was no family history of adrenal insufficiency or
urogenital anomalies (Fig. 1). Previous genetic testing
included mitochondrial DNA (mtDNA) sequencing which
revealed no relevant pathogenic variants.
Materials and Methods
Ethical compliance
Our study was approved by Mayo Clinic IRB and ethics
committees.
Figure 1. Patient family history. Black arrow is depicting the affected
subject. Patient was diagnosed with hypospadias and skin
hyperpigmentation. There was no family history of adrenal
insufficiency.
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Testing
In order to identify the genetic etiology, WES was per-
formed. The patient and his family were counseled about
the purpose, benefits, and limitations of WES. Addition-
ally, possible test results were reviewed with patient and
parents. The protections and limitations of GINA
(Genetic Information Nondiscrimination Act) were dis-
cussed. The patient’s mother was provided a copy of the
informed consent. Samples from the proband, mother,
and father were collected. Due to the history of HELLP
syndrome in the patient’s mother, acylcarnitine testing
was also performed in the proband, which was normal.
Whole-exome sequencing
Clinical WES was performed by GeneDX (XomeDxPlus).
Briefly, genomic DNA was extracted from the proband
and parental samples. As described in the clinical testing
methodology by GeneDX, the Agilent Clinical Research
Exome capture kit was used for exome enrichment and
sequencing was done on an Illumina HiSeq 2000 that
generates 100 bp paired-end reads. Bidirectional sequence
was assembled, aligned to reference gene sequences based
on human genome build GRCh37/UCSC hg19, and ana-
lyzed for sequence variants using a proprietary analysis
tool (Xome Analyzer, GeneDx). Sanger sequencing was
used to confirm all potentially pathogenic variants identi-
fied in this individual. Sequence alterations were reported
according to the Human Genome Variation Society
(HGVS) nomenclature guidelines.
Molecular modeling
The sequence of human cholesterol side-chain cleavage
enzyme, mitochondrial 11A1 (Cyp11A1), a protein
encoded by the gene (CYP11A1), was taken from the
NCBI Reference Sequence: NM_000781.2: NP_000772.2;
and was used for modeling. Monte Carlo simulations
were performed on the mutant to allow local regional
changes after the p.E314K variant was introduced. Addi-
tional details can be found in the Appendix S1.
Results
WES revealed compound heterozygous variants in the
proband, including a novel paternally inherited CYP11A1
splice site variant (Chr15(GRCh37): g.74640240C>T,
NM_000781.2: c.425+1G>A) and a previously reported
CYP11A1 missense variant (Chr15(GRCh37):
g.74635368C>T, NM_000781.2: c.940G>A) that was
maternally inherited (Table 1). The c.425+1G>A variant
is considered pathogenic and the c.940G>A (p.E314K)
variant likely pathogenic based on HGVS guidelines. Vari-
ants were deposited in ClinVar under accession numbers
RCV000403766.1 and RCV000413593.1, respectively.
Discussion
Adrenal insufficiency (AI) is characterized by defects in
cortisol, aldosterone, and sexual hormone production
(Miller 2017). Common manifestations of the disease
include hyperpigmentation, hypoglycemia, lethargy, fati-
gue, muscle weakness, weight loss, dizziness and hypoten-
sion (Ucar et al. 2016). Biochemical criteria for AI
diagnosis include very low serum cortisol levels
(<80 nmol/L), and elevated ACTH plasma levels (>200
pmol/L) (Neary and Nieman 2010; Ucar et al. 2016).
AI can be produced either by congenital or acquired
pathologies. Congenital causes include autosomal reces-
sive congenital lipoid adrenal hyperplasia (CAH, MIM#
201710) (caused by pathogenic variants in STAR); con-
genital adrenal insufficiency with partial or complete
46XY sex reversal (AICSR, MIM# 613743) (caused by
variants in CYP11A1), congenital adrenal hyperplasia due
to 3b-hydroxysteroid dehydrogenase 2 deficiency (caused
by variants in HSD3B2); congenital adrenal hyperplasia
due to 21-hydroxylase deficiency (MIM# 201910) (caused
by variants in CYP21A2); 11b-hydroxylase deficiency
(caused by variants in CYP11B1) which can result in
autosomal recessive congenital adrenal hyperplasia
(MIM# 202010) or autosomal dominant glucocorticoid-
remediable aldosteronism (MIM# 103900); 17-a-hydroxy-
lase/17,20-lyase deficiency (MIM# 202110) (caused by
variants in CYP17A1); P450 oxidoreductase deficiency
(MIM# 201750) (caused by variants in POR) (Katsumata
et al. 2002; Hiort et al. 2005; Slominski et al. 2015);
familial glucocorticoid deficiency (FGD) (caused by
defects in STAR, MC2R, MRAP, MCM4, NNT, TXNRD2,
GPX1 and PRDX3) (Miller 2017); and autoimmune disor-
ders such as polyendocrinopathy syndrome type I, with
or without reversible metaphyseal dysplasia (MIM#
240300, caused by defects in AIRE) (Fig. 2) (Miller and
Auchus 2011; Turcu and Auchus 2015; Manna et al.
2016). Acquired causes, include infectious diseases
(Waterhouse-Frederichsen syndrome), vascular diseases
(hemorrhage and coagulopathy), surgery (bilateral
adrenalectomy), and exposure to certain medications (ri-
fampicin, phenytoin, and ketoconazole) (Zaloga and
Marik 2001).
Congenital AI is an autosomal recessive disorder char-
acterized by elevated ACTH and plasma renin levels with
low or absent adrenal steroids. AI has two different
expression forms: classical and nonclassical (Pomahacova
et al. 2016). The classical phenotypic spectrum ranges
from miscarriage and prematurity during pregnancy, to
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complete under-androgenization and severe early or late
onset adrenal failure at postnatal stages. In the classic pre-
sentation of the disease, clitoromegaly is a common find-
ing for feminization of external genitalia in 46XY patients
(Neary and Nieman 2010). In the nonclassic form,
patients can present with adrenal function impairment
with minimal effects on primary sexual characteristics and
male patients may present with only cryptorchidism or
hypospadias (Hauffa and Hiort 2011; Tee et al. 2013).
Adrenal insufficiency can be caused by pathogenic vari-
ants in CYP11A1. CYP11A1 is located at chromosome
15q23–24, and encodes the cytochrome P450 side-chain
cleavage enzyme (P450scc), which initiates steroidogenesis
(Fig. 3). P450scc catalyzes the conversion of cholesterol to
pregnenolone and isocaproic aldehyde in the inner mito-
chondrial membrane. These reactions represent the first
step for steroid-hormone biosynthesis. Biallelic pathogenic
variants in CYP11A1 are a rare cause of adrenal
Table 1. Causative variants in disease genes associated with reported phenotype.
CYP11A1 phenotype MOI Variant
Variant
location Zygosity Inheritance Classification
Adrenal insufficiency, congenital, 46XY sex reversal,
partial or complete (MIM #613743)
AR IVS2+1G>A NP_000772.2 Heterozygous Father Pathogenic
c.425+1G>A NM_000781.2
g.74640240C>T NG_007973.1
AR p.Glu314Lys NP_000772.2 Heterozygous Mother Likely
pathogenicc.940G>A NM_000781.2
g.74635368C>T NG_007973.1
Figure 2. Steroid hormone synthesis diagram and related pathologies (1–3).
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insufficiency in patients (Tajima et al. 2001; Hauffa and
Hiort 2011; Parajes et al. 2011, 2012; Tee et al. 2013).
Compared with CAH, AI patients can present mild to
severe adrenal insufficiency symptoms without adrenal
hyperplasia, these symptoms can manifest at any time
from infancy to early childhood, depending on the degree
of P450scc dysfunction (Hauffa and Hiort 2011; Tee et al.
2013).
In this report, we found a c.425+1G>A pathogenic
variant in CYP11A1 in our 12-year-old male patient.
This splice site variant disrupts the canonical splice
donor site in intron 2, and is predicted to cause abnor-
mal gene splicing. The c.425+1G>A variant is a rare
variant and has not been seen in NHLBI Exome
Sequencing Project or the Genome Aggregation Database
(gnomAD) (insert database references) (Table 1). To the
best of our knowledge, the c.425+1G>A pathogenic vari-
ant in CYP11A1 has not been reported previously.
Regarding ACTH levels, records indicate no cosyntropin
stimulation test was performed, and perhaps would have
led to earlier diagnosis of adrenal insufficiency and initi-
ation of steroids.’
In addition to the c.425+1G>A variant, we identified a
missense variant (c.940G>A p.(E314K)) in exon 5. The
p.(E314K) variant is a nonconservative amino acid substi-
tution, which likely impacts secondary protein structure
as these residues differ in polarity, charge, and size. How-
ever, this substitution occurs at a position that is not con-
served, and in silico analysis is inconsistent in its
predictions as to whether or not the variant is predicted
to be damaging. The p.(E314K) variant is a strong candi-
date for a pathogenic variant. In two unrelated individu-
als with primary adrenal insufficiency, the p.(E314K)
variant was previously reported; one of this cases was
accompanied by another CYP11A1 variant in trans with
another variant whereas the other reported case had no
additional molecular findings (Chan et al. 2015). Accord-
ing with the NHLBI ESP Exome Sequencing Project,
Figure 3. Schematic representation of P450 side-chain cleavage (CYP11A1) and its interaction with the E314K variant.
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p.(E314K) variant is present in 29/8592 cases from indi-
viduals of European American ancestry and in 710/
277190 individuals in gnomAD, including four homozy-
gotes, (Table 1) suggesting that this variant may retain
partial function and could result in disease when in trans
cwith another inactivating mutation. Molecular modeling
of the p.E314K variant was performed and Monte Carlo
simulations suggest that the orientation of the E and K
residues flips and the mutant may disrupt cholesterol
binding and lead to minor changes in helicity at the end
of the helix when K314 is introduced (Fig. 3).
Conclusion
In conclusion, the compound heterozygous presence of
the c.425+1G>A and p.(E314K) variants in CYP11A1
found in this patient, explain the reported primary adre-
nal insufficiency diagnosis. The c.425+1G>A splice variant
in CYP11A1 is novel and may be a pathogenic variant for
AI, the p.(E314K) variant has been cited in the literature
as pathogenic when present as a compound heterozygous
variant (Chan et al. 2015). In addition to the novel vari-
ant description, this case remarks the application of WES
as a powerful diagnostic tool to provide accurate diagno-
sis, medical management and family counseling to
improve patient care.
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